search
Back to results

Intermittent Normoxia Reduces Myocardial Reperfusion Injury (INCPB)

Primary Purpose

Hyperoxia

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
intermittent normoxia
Sponsored by
Central South University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hyperoxia focused on measuring cardiopulmonary bypass

Eligibility Criteria

25 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • rheumatic heart valve disease requiring selective aortic or double valve(aortic and mitral valve) replacement

Exclusion Criteria:

  • infective endocarditis congenital valve disease previous cardiac surgery complicated with diabetes, coronary artery disease, hypertension or peripheral vascular disease.

receiving aspirin, corticosteroids, angiotensin-converting enzyme inhibitors or statin perioperatively

Sites / Locations

  • Department of Cardiothoracic Surgery, Xiangya Hospital, Central South UniversityRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Intermittent normoxia

Arm Description

Repeated brief normoxic reperfusion during cardioplegia arrest in adult valve replacement

Outcomes

Primary Outcome Measures

plasma concentration of troponin I

Secondary Outcome Measures

gene expression of TNFa, IL-6, and IL-10 in myocardium

Full Information

First Posted
May 3, 2011
Last Updated
May 5, 2011
Sponsor
Central South University
search

1. Study Identification

Unique Protocol Identification Number
NCT01348906
Brief Title
Intermittent Normoxia Reduces Myocardial Reperfusion Injury
Acronym
INCPB
Official Title
Effect of Intermittent Normoxic Cardiopulmonary Bypass on Myocardial Reperfusion Injury in Adult Valve Replacement
Study Type
Interventional

2. Study Status

Record Verification Date
May 2011
Overall Recruitment Status
Unknown status
Study Start Date
May 2011 (undefined)
Primary Completion Date
July 2011 (Anticipated)
Study Completion Date
July 2011 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
Central South University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study aims to determine the effect of intermittent normoxic cardiopulmonary bypass (CPB) on inflammatory response, oxidative stress and myocardial reperfusion injury in adult patients undergoing valve replacement. The investigators hypothesized that nuclear factor kappa B (NFkB) was involved in regulating gene expression of myocardial inflammatory factor.
Detailed Description
Methods:Patients meeting the requirement will be randomized into 2 groups: the control group received hyperoxic reperfusion (PaO2 180-250 mmHg) throughout CPB as routine; the treatment group underwent 3 cycles of 5/5 min normal/high oxygenation (PaO2 80-150/180-250 mmHg) during cardioplegia arrest, and maintained the same hyperoxia as the control group in the rest time of CPB. The clinical data of inotropes requirement, drainage, ventilation and intensive care time will be recorded. Venous blood samples will be taken perioperatively for detecting concentration of troponin I (cTnI), tumor necrosis factor-α , interleukin-6, 10, and malondialdehyde (MDA). Atrial biopsies will be removed before cardioplegia arrest and 30min after aortic de-clamping to determine the extent of neutrophil infiltration (myeloperoxidase activity), NFkB binding DNA activity, and gene expression of inflammatory factors (TNF-α, IL-6, 10). Statistical analysis:A sample size of at least 32 patients in each group was needed to have a power of 90%, significance at the two-side 5% level, on the basis that a SD of 0.2 ng/ml and a difference in peak serum cTnI release of about 0.15 ng/ml between control and conditioned patients was determined. Expected Results: The treatment group will have significantly lower release of cTnI, inflammatory factors, and MDA during CPB and afterwards. Intermittent normoxia may be related to less myocardial inflammation characterized by decreased myeloperoxidase activity, gene expression of inflammatory factors, the later may result from reduced activity of NFkB binding to DNA after reperfusion.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hyperoxia
Keywords
cardiopulmonary bypass

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
70 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intermittent normoxia
Arm Type
Experimental
Arm Description
Repeated brief normoxic reperfusion during cardioplegia arrest in adult valve replacement
Intervention Type
Procedure
Intervention Name(s)
intermittent normoxia
Intervention Description
3 cycles of 5/5 min normoxia/hyperoxic reperfusion during cardioplegia arrest in adult valve replacement
Primary Outcome Measure Information:
Title
plasma concentration of troponin I
Time Frame
within the first 24h after cardiac surgery
Secondary Outcome Measure Information:
Title
gene expression of TNFa, IL-6, and IL-10 in myocardium
Time Frame
30 min after aotic de-clamping

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: rheumatic heart valve disease requiring selective aortic or double valve(aortic and mitral valve) replacement Exclusion Criteria: infective endocarditis congenital valve disease previous cardiac surgery complicated with diabetes, coronary artery disease, hypertension or peripheral vascular disease. receiving aspirin, corticosteroids, angiotensin-converting enzyme inhibitors or statin perioperatively
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Shengxi Chen, M.D.
Phone
86-731-89753413
Email
shengxi.chen@hotmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Li Li, M.D.
Phone
86-731-84327097
Email
lovelily0920@yahoo.cn
Facility Information:
Facility Name
Department of Cardiothoracic Surgery, Xiangya Hospital, Central South University
City
Changsha City
State/Province
Hunan
ZIP/Postal Code
410008
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wanjun, Luo
Phone
86-731-89753703
Email
luowanjun@yahoo.com
First Name & Middle Initial & Last Name & Degree
Li Li, M.D.

12. IPD Sharing Statement

Learn more about this trial

Intermittent Normoxia Reduces Myocardial Reperfusion Injury

We'll reach out to this number within 24 hrs